(Q48340234)

English

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.

scientific article published on 10 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

author name string

A K Burnett

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

D Grimwade

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

J V Jovanovic

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

J Craig

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

M F McMullin

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

J Kell

7

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

K Wheatley

8

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

J A L Yin

9

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

A Hunter

10

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

D Milligan

11

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

N H Russell

12

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup

13

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

publication date

10 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

27

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

843-851

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

https://scigraph.springernature.com/pub.10.1038/leu.2012.360

0 references

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Treatment advances have not improved the early death rate in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

21 January 2018

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.360

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.360

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

release_ptvyob3bm5bcnnx5kf76ho2zl4

1 reference

https://api.fatcat.wiki/v0/release/ptvyob3bm5bcnnx5kf76ho2zl4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23222369

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48340234&oldid=1843196141"